Balanced news tone
News Sentiment
4523 sentiment intelligence
Eisai Co., Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
51
Balanced news tone
19 relevant articles
News tone and price action are not far from neutral.
86/100 classification confidence.
directly relevant articles
high-authority source matches
+1.0% over one week, +13.7% over four weeks, trend inactive, and near fair-value range.
How Investors May Respond To Eisai (TSE:4523) Advancing Lecanemab Data And New CNS Oncology Filings
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
86/100 classification
One-week reaction
1.0%
Price digesting
Trend fit
Trend inactive
13.7% over four weeks
Fair value
-18.6%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
2
Neutral
17
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
simplywall.st
Direct company coverage
How Investors May Respond To Eisai (TSE:4523) Advancing Lecanemab Data And New CNS Oncology Filings
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 17:02
- Source
- simplywall.st
MSN
Direct company coverage
Eisai Co Ltd (4523)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 12:20
- Source
- MSN
simplywall.st
Direct company coverage
Eisai (TSE:4523) Could Be 15% Below Fair Value As Pipeline News Builds
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 06:12
- Source
- simplywall.st
Ad Hoc News
Direct company coverage
Eisai outlines its long-term growth strategy as a global pharma player
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 04 Jul 2026 16:05
- Source
- Ad Hoc News
Seeking Alpha
Direct company coverage
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day - Slideshow (OTCMKTS:ESAIY) 2026-05-25
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 25 May 2026 07:00
- Source
- Seeking Alpha
Market source
Direct company coverage
How Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value Outlook
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 21 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Eisai (TSE:4523) Valuation Check After Recent Share Price Pullback And LEQEMBI Growth Story
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Eisai (TSE:4523) Valuation Check As Recent Momentum Meets Mixed Long Term Returns
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Assessing Eisai (TSE:4523) Valuation After Mixed Share Price Momentum And LEQEMBI Expectations
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Feb 2026 08:00
- Source
- Market source
Reuters
Direct company coverage
Eisai strikes Japan licensing deal with Shanghai Henlius Biotech
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 05 Feb 2026 08:00
- Source
- Reuters
Biogen
Direct company coverage
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Dec 2025 08:00
- Source
- Biogen
Biogen
Direct company coverage
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Nov 2025 08:00
- Source
- Biogen
TradingView
Direct company coverage
ETFs Investing in Eisai Co., Ltd. Stocks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Sep 2025 03:10
- Source
- TradingView
Eisai
Direct company coverage
Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2025 07:00
- Source
- Eisai
Reuters
Direct company coverage
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jul 2024 07:00
- Source
- Reuters
Eisai
Direct company coverage
To Develop Japan’s First Blood Biomarker-Based Diagnostic Workflow for DementiaShimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research | News ReleaseNews Release：2022
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Nov 2022 08:00
- Source
- Eisai
Biogen
Direct company coverage
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Mar 2022 07:00
- Source
- Biogen
Eisai
Direct company coverage
EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN | News ReleaseNews Release：2020
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Dec 2020 08:00
- Source
- Eisai
Eisai
Direct company coverage
Eisai co-establishes “Global Health Innovative Technology Fund,” Japan's first public–private partnership to eliminate infectious disease in developing countries | Patients and People
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 11 Jul 2013 07:00
- Source
- Eisai